Randomized phase III trial of erlotinib (E) versus docetaxel (D) as second-or third-line therapy in patients with advanced non-small cell lung cancer (NSCLC) who …
Y Okano, M Ando, K Asami, M Fukuda, H Nakagawa… - 2013 - ascopubs.org
8006 Background: E and D are standard cares for previously treated patients with advanced
NSCLC. Although E shows significant clinical benefits over best supportive care in the EGFR …
NSCLC. Although E shows significant clinical benefits over best supportive care in the EGFR …
Randomized phase III trial of erlotinib versus docetaxel as second-or third-line therapy in patients with advanced non–small-cell lung cancer: Docetaxel and Erlotinib …
T Kawaguchi, M Ando, K Asami, Y Okano… - Journal of clinical …, 2014 - ascopubs.org
Purpose To investigate the efficacy of erlotinib versus docetaxel in previously treated
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …
patients with advanced non–small-cell lung cancer (NSCLC) in an epidermal growth factor …
Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised …
MC Garassino, O Martelli, M Broggini, G Farina… - The lancet …, 2013 - thelancet.com
Background Erlotinib is registered for treatment of all patients with advanced non-small-cell
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …
lung cancer (NSCLC). However, its efficacy for treatment of patients whose tumours are …
Erlotinib versus chemotherapy (CT) in advanced non-small cell lung cancer (NSCLC) patients (p) with epidermal growth factor receptor (EGFR) mutations: Interim …
R Rosell, R Gervais, A Vergnenegre… - Journal of clinical …, 2011 - ascopubs.org
7503 Background: EGFR tyrosine kinase activating mutations are present in 10-26% of
NSCLC tumors and are associated with increased response to gefitinib and erlotinib …
NSCLC tumors and are associated with increased response to gefitinib and erlotinib …
[HTML][HTML] Erlotinib therapy after initial platinum doublet therapy in patients with EGFR wild type non-small cell lung cancer: results of a combined patient-level analysis …
RU Osarogiagbon, F Cappuzzo… - … lung cancer research, 2015 - ncbi.nlm.nih.gov
Background The clinical benefit of erlotinib in treating epidermal growth factor receptor
(EGFR) wildtype non-small cell lung cancer (NSCLC) has been questioned. We examined …
(EGFR) wildtype non-small cell lung cancer (NSCLC) has been questioned. We examined …
Randomized open-label non-comparative multicenter phase II trial of sequential erlotinib and docetaxel versus docetaxel alone in patients with non-small-cell lung …
JB Auliac, C Chouaid, L Greiller, I Monnet, H Le Caer… - Lung cancer, 2014 - Elsevier
Background Concomitant administration of erlotinib with standard chemotherapy does not
appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but …
appear to improve survival among patients with non-small-cell lung cancer (NSCLC), but …
Retrospective efficacy and safety analyses of erlotinib, pemetrexed, and docetaxel in EGFR-mutation-negative patients with previously treated advanced non …
A Nishiyama, N Katakami, H Yoshioka, M Iwasaku… - Lung Cancer, 2015 - Elsevier
Objective Several guidelines recommend erlotinib, pemetrexed, or docetaxel for second-line
chemotherapy in patients with advanced non-squamous non-small-cell lung cancer …
chemotherapy in patients with advanced non-squamous non-small-cell lung cancer …
Efficacy and safety of PF299804 versus erlotinib (E): A global, randomized phase II trial in patients (pts) with advanced non-small cell lung cancer (NSCLC) after …
MJ Boyer, FH Blackhall, K Park, CH Barrios… - Journal of Clinical …, 2010 - ascopubs.org
LBA7523 Background: PF299804, a potent, irreversible inhibitor of human epidermal growth
factor receptor (HER)-1/EGFR,-2, and-4 tyrosine kinases (TK), is active in E-sensitive and …
factor receptor (HER)-1/EGFR,-2, and-4 tyrosine kinases (TK), is active in E-sensitive and …
A phase II trial of erlotinib in patients with EGFR wild-type advanced non-small-cell lung cancer
T Kobayashi, T Koizumi, T Agatsuma, M Yasuo… - Cancer chemotherapy …, 2012 - Springer
Purpose There is as yet no optimal treatment regimen for patients with epidermal growth
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …
factor receptor (EGFR) gene wild-type non-small-cell lung cancer (NSCLC) that has …
A multicenter, randomized, open-label, phase II trial of erlotinib versus etoposide plus cisplatin with concurrent radiotherapy in unresectable stage III non-small cell …
L Xing, G Wu, L Wang, JC Li, J Wang, Z Yuan, M Chen… - 2017 - ascopubs.org
8531 Background: Concurrent chemoradiotherapy is the standard treatment for patients (pts)
with unresectable stage IIIA/IIIB NSCLC. In EGFR mutant pts, tyrosine kinase inhibitor (TKI) …
with unresectable stage IIIA/IIIB NSCLC. In EGFR mutant pts, tyrosine kinase inhibitor (TKI) …
相关搜索
- cell lung cancer
- lung cancer therapy in patients
- randomized phase performance status
- lung cancer egfr mutation
- randomized phase agent erlotinib
- randomized phase patients pts
- phase ii trial of erlotinib
- randomized phase standard chemotherapy
- randomized phase efficacy and safety
- performance status standard chemotherapy
- lung cancer erlotinib in patients
- randomized phase failure of chemotherapy
- performance status agent erlotinib
- standard chemotherapy agent erlotinib